Peyronie's disease is a fibrotic disorder of the tunica albuginea of the penis resulting in varying degrees of penile curvature and sexual dysfunction. Diagnosis of the disorder is made by detailed sexual history and focused physical examination. A wide range of medical treatments has been employed to treat the disorder. Verapamil treatment administered by intraplaque injection is supported by generally consistent randomized controlled trials (RCT). Some RCT evidence exists to support the use of colchicine, potaba, L-carnitine and liposomal superoxide dismutase. Future studies of medical efficacy should focus on improving RCT design, implementation and results reporting to improve the quality of evidence generated by each study. The surgical treatment of Peyronie's disease is a viable and recommended alternative for men with compromised sexual function due to severe curvature or lesions causing penile instability. The choice of corrective procedure should be tailored to each patient after a detailed evaluation of disease severity and sexual function.
Introduction
Peyronie's disease (PD) is a fibrotic disorder of the tunica albuginea of the penis. Although the naming of the disorder has been attributed to François Gigot de la Peyronie, surgeon to king Louis XIV of France, descriptions in the literature consistent with the disease can be found as early as 1265. 1 This review considers the epidemiology, natural history and diagnostic evaluation of PD. We describe the medical and surgical therapies from both a historical and contemporary perspective. Special emphasis is placed upon the quality of evidence underlying current medical and surgical treatment options.
Epidemiology
Information on the prevalence of PD is mixed but generally suggests that approximately 5% of men aged 50 years or older will experience the disease. The most convincing population-based data come from a community-based cross-sectional study of 8000 men from Germany, 3.2% of whom endorsed symptoms consistent with PD. 2 A linear trend was observed for the prevalence of the disorder ranging from 1.5% for 30-to 39-year-old men to 6.5% for men over 70. A similar prevalence was seen among 1100 men screened for prostate cancer in southern Brazil, with 3.7% of men over 50 reporting symptoms of penile angulation or plaque. 3 In another prostate screening program, penile plaque was identified in 8.9% of men. 4 Selection bias likely accounts for the 16% prevalence reported from tertiary referral centers treating men with erectile dysfunction (ED). 5 Historical reports of prevalence as low as 0.4% 6 contribute to the belief that PD is an uncommon disorder. Other authors have estimated the prevalence to approximate 1%. 7 To date, no convincing cohort data have clearly characterized the incidence and/or prevalence of PD among the general population; however, the true value likely ranges between 3 and 9% of adult men, depending heavily upon the age distribution of the group studied.
Natural history of Peyronie's disease
Peyronie's disease is a progressive disorder with nearly half of men having disease worsening if left untreated. A recent study by Mulhall et al. 8 of 246 men recently diagnosed with PD and followed for 1 year without treatment demonstrated that 12% improved, 40% remained stable and 48% worsened. This is different from the commonly held belief that up to 30-40% of untreated PD will improve spontaneously. Clinicians often separate the disease into active and quiescent phases based upon the clinical and diagnostic evaluation. 9 The active phase is characterized by increasing plaque size or penile curvature and penile pain. Although it may be true in many men that the active phase lasts from 12 to 18 months from the onset of disease, a significant proportion of men will experience continued progression after this time point. One goal of medical therapy is to shorten the acute phase of disease to promote stabilization of the plaque and decrease progression of disease. The chronic phase of disease is characterized by the absence of penile pain and a period of unchanging curvature or plaque size. 9 Etiology of Peyronie's disease Although many hypotheses have been put forth, the exact etiology of PD remains unknown and is likely multifactorial. The most promising hypothesis to explain the etiology of PD is one of penile trauma followed by abnormal wound healing. 7, 10, 11 An initial episode of buckling of the tunica albuginea results in shear forces applied to the penis. Subsequent abnormalities in wound healing may result in formation of a fibrous scar. A recent excellent review summarizes the main features of normal and abnormal wound healing in PD. 1 Transforming growth factor (TGF)-b has been shown in cell culture and animal models to be an important profibrotic mediator of plaque formation. Enzymes in the matrix metalloprotein family have important antifibrotic properties. The balance between proand antifibrotic enzymatic processes likely contributes significantly to the development of plaques and subsequent penile curvature. Animal models targeting these molecular mechanisms have shown promise in decreasing penile curvature and plaque size.
Genetic factors or inflammatory responses may be responsible for or contribute to some cases of Peyronie's disease. For example, the Kelami syndrome, also known as urethral manipulation syndrome, is described as ventral penile curvature occurring after urethral manipulation. [12] [13] [14] Sonographic evidence suggests that the underlying mechanism for penile curvature in this setting is one of periurethral scarring, 14 perhaps secondary to inflammation from urethral manipulation. A high prevalence of PD (32%) has been seen in patients with Paget's disease, a chronic skeletal condition leading to painful deformities of bone. 15 The presence of Dupuytren's contractures among some men with Peyronie's disease suggests that a genetic predisposition to scarring and fibrosis may be associated with tunica albuginea fibrosis and scarring. 16 
Clinical manifestations
Loss of flexibility of the tunica albuginea from fibrosis or calcification results in differential expansion of the tunica during erection with subsequent penile curvature. The degree of curvature and volume of plaque is highly variable upon presentation. Curvature can range from nearly straight (151) to 1801 in the most severe cases. Plaques can be single or multiple and are associated with a variety of penile deformities. Although the most common direction of curvature is dorsal, ventral, lateral and complex curvatures are frequently seen. Deformities range from 'notching' to circumferential 'hourglass' defects. Penile shortening is a commonly reported symptom of great concern to patients.
Multiple reports have described the high prevalence of erectile dysfunction (ED) in men with PD (80-100%) [17] [18] [19] but a recent report challenged this assertion with a much lower prevalence (36%). 20 Kendirci et al. 21 confirmed that diabetes is a risk factor for vasculogenic ED among older men with PD. Although it is clear that some men with PD also have ED, it is likely that the occurrence of ED in these men is related to advancing age and comorbid medical conditions rather than PD itself.
Although there are few reports in the literature of the emotional and psychosocial impact of PD, clinicians clearly recognize its impact. Patients often have a variety of psychosexual complaints, including poor self-image, 22 emotional and relationship difficulties. 23 Although many clinical trials in treatment for PD utilize measures of ED as a primary outcome measure, no specific quality of life measure has yet been published for the disorder.
Patient evaluation

History
The evaluation of a man suspected of having PD should begin with a thorough medical history. This This data collection can be facilitated by utilizing a disease-specific questionnaire. 24 Unfortunately, to date, no validated surveys have been published to address issues specific to PD. A patient-supplied photograph of the erect penis can be beneficial in characterizing the degree of deformity, although this may underestimate the degree of curvature. 25 Physical examination A directed physical examination is crucial for determining disease severity. The key components of the examination include the genitalia and extremities. Stretched penile length is a critical component of the evaluation as penile shortening is a common complaint of PD patients and can worsen over time. Plaque characteristics should be noted for their position, size, tenderness to palpation, texture (that is, calcifications) and number. The hands should be examined for the cord-like thickening of Dupuytren's contractures. Lederhose's disease can manifest as nodules on the sole of the feet; plantar fasciitis occurs in up to 50% of the population making this a nonspecific finding. 7 
Maneuvers to assess lesion severity
Erectile capacity is best assessed through a detailed patient history that includes the completion of a validated erectile function questionnaire (International Index of Erectile Function (IIEF), Sexual Health Inventory for Men (SHIM) and so on). In situations of uncertainty regarding a patient's erectile function, a cavernosal injection and selfstimulation (CIS) test should be performed using vasoactive agents. In addition to assessing erectile capacity, the CIS test may provide the most accurate means of measuring penile curvature. 25 After erection induction, a protractor can be used to determine the degree of penile curvature. Penile nodules can be measured with calipers or a ruler.
Imaging and vascular studies
Imaging modalities can assist in identifying abnormalities of the tunica albuginea and corpora cavernosa. Duplex Doppler ultrasound is used to assess vascular health and to estimate the degree of curvature after CIS. 26 B-mode ultrasound is useful for measuring the extent of fibrosis or calcification of the tunica albuginea, corpora cavernosa and septum. Penile ultrasound identifies calcifications more accurately than X-ray, CT scan or magnetic resonance imaging. 27, 28 This relatively low-cost and minimally invasive technique can also demonstrate tunica albuginea and septal thickening or fibrosis. 29 Tunica thickness varies by location (1-3 mm in normal individuals) and is often increased in the Peyronie's plaque. 30 Medical therapy A wide range of medical therapies have been utilized for the treatment of Peyronie's disease. To evaluate the strength of evidence supporting the use of one therapy over another, randomized controlled trials (RCT) or systematic reviews of RCTs were considered the strongest evidence, followed by prospective and retrospective cohort studies, case series and expert opinion. 31 Where RCT evidence existed, weaker forms of evidence were not examined (Table 1) .
Oral therapy Potaba. Potaba (potassium paraaminobenzoate) likely exerts its effects through antifibrotic and anti-inflammatory mechanisms. It has been shown in observational studies to be an effective treatment for PD. 47, 48 A single placebo-controlled doubleblind RCT has been conducted to evaluate its effectiveness in either decreasing curvature or the size of the penile plaque. 39 In this study, 103 men with early disease (o12 months) were randomized to Potaba 3 g p.o. four times per day or placebo. Among patients treated for a full 12 months, Potaba treatment was associated with a 74% decrease in plaque size vs 50% decrease for placebo (P ¼ 0.016). Pain relief was experienced equally in both groups and no difference in adverse effects was noted. Although well designed, the study suffered from the lack of an intention to treat analysis, no evidence of a post-randomization blinding mechanism and its small sample size. Despite the limited data, Potaba holds promise in terms of stabilizing preexisting lesions and preventing new plaques from forming; however, frequent dosing and high cost may limit its use.
L-carnitine. L-carnitine is hypothesized to act by increasing mitochondrial respiration and decreasing free radical formation. 49 Reported side effects have included mild euphoria 43 and gastrointestinal upset with larger doses (44 g per day). 50 The results of randomized trials have been mixed. One trial comparing tamoxifen vs L-carnitine demonstrated decreased plaque size and curvature in the L-carnitine arm and found that L-carnitine provided great pain reduction and fewer side effects than tamoxifen. 43 When combined with intralesional
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Weidner et al. 33 Conversely, an RCT of 236 men comparing vitamin E þ L-carnitine to vitamin E alone or placebo did not demonstrate benefit after 6 months of treatment. 41 Incomplete blinding and lack of intention to treat analyses potentially introduce bias into these trials and could account for the positive results. Further, it is possible that the dose chosen for these trials (1 g b.i.d.) was insufficient to achieve a physiological response as one recent review estimated the minimum dosage necessary for effect to be a minimum of 3-3.5 g per day. 50 Vitamin E. Vitamin E (a-tocopherol) is thought to be active through its antioxidant properties as has been demonstrated in numerous in vitro studies. 51, 52 It is unclear, however, whether these effects are significant in human studies. 52 In a randomized prospective trial of 236 men with chronic PD, no benefit of vitamin E was noted over the course of the 6-month trial. 41 Another small trial (n ¼ 30) failed to show benefit. 38 However, when vitamin E was combined with colchicine, a single-blind RCT (n ¼ 45) in men with mild, early PD, demonstrated significantly decreased plaque size in the intervention arm 40 relative to treatment with ibuprofen. Randomized trials have failed to demonstrate that vitamin E alone significantly improves outcomes relative to placebo.
Colchicine. Colchicine has demonstrated antiinflammatory properties often used for the treatment of gout or malignancies 53, 54 and has been long used for the treatment of PD. Although a small trial (n ¼ 45) comparing colchicine with vitamin E to placebo demonstrated decreased plaque size in the early, inflammatory phase of PD, 40 a subsequent somewhat larger RCT (n ¼ 84) failed to demonstrate a significant treatment effect for the 78 men who completed colchicine therapy. 46 Significant gastrointestinal side effects have been reported along with the potential for bone marrow suppression. 51 For chronic colchicine use, a complete blood count should be obtained every 3-4 months to monitor for this adverse effect. Given the mixed findings from two RCTs, further data are needed to strongly recommend colchicine therapy for PD.
Tamoxifen. Tamoxifen is a nonsteroidal antiestrogen whose mechanism of action with regard to PD treatment remains unclear. It may act through a reduction in the production of TGF-b by fibroblasts in the tunica albuginea. 1, 55 Uncontrolled studies have demonstrated moderate benefit. 56 One randomized, placebo-controlled study did not demonstrate benefit after 3 months of treatment in terms of decreased penile curvature or plaque size (P40.05). 42 Tamoxifen was also shown to be inferior to L-carnitine in terms of reducing pain, penile curvature and plaque size during the acute phase of PD. 43 These data do not support the routine use of tamoxifen to treat PD.
Pentoxifylline. Pentoxifylline is a nonspecific PDE-5 inhibitor used for a wide range of medical applications. It has been used in kidney transplants, open heart surgery, dermatological conditions and radiation-induced fibrosis as a means of decreasing inflammation and fibrosis [57] [58] [59] [60] [61] [62] and is commonly used to treat claudication and symptomatic cerebral atherosclerosis. 63 The potential benefit of pentoxifylline is predicated on data from in vitro and in vivo models. Pentoxifylline added to fibroblast culture resulted in an upregulation of cAMP and decreased collagen I production, 64 suggesting potential benefit for the abnormal collagen production seen in PD. These researchers continued by demonstrating decreased levels of profibrotic factors and decreased size of fibrotic plaques after treatment with pentoxifylline in a rat model of Peyronie's disease. 64 Additional in vitro evidence revealed an upregulation of osteoclastic activity after treatment with pentoxifylline, but the significance of this finding in the corpora cavernosa is unclear. 65 One 66 and decrease calcifications in newonset Peyronie's disease, 67 consistent with one hypothesized mechanism of action. Side effects are relatively mild, most commonly nausea (14%), dizziness (9%) and headache (3.5%). 68 Pentoxifylline costs roughly $60 a month without insurance and 400 mg is given orally three times daily. Despite the potential for benefit based upon its mechanism of action and preliminary clinical data, prospective cohort and ultimately RCT data are needed to support the use of pentoxifylline for the routine treatment of PD.
Procarbazine. Procarbazine, a cytotoxic medication, is of historical interest and has been found to be less effective than vitamin E with significant toxic side effects. 69 Uncontrolled series demonstrated minimal evidence of efficacy in addition to significant gastrointestinal side effects prompting discontinuation of therapy.
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Topical therapy and iontophoresis Topical verapamil. In a pilot study comparing topical verapamil to the calmodulin blocker, trifluoperazine and placebo, trifluoperazine was found to have significant side effects including anxiety, agitation, blurred vision, insomnia and depression. 36 Topical verapamil hydrochloride applied twice daily (0.5 ml) over the entire shaft of the penis resulted in a significant reduction in curvature, plaque size and improvements in erectile function at three months. However, conclusions drawn from this study are limited due to the absence of intent-totreat analysis and a poor description of treatment allocation. As a result, controversy remains as to whether topical administration of verapamil can truly penetrate the tunica albuginea. 72 
Iontophoresis
Superoxide dismutase (orgotein, Lipoxysan). Superoxide dismutase is a potent scavenger of oxygen free radicals that has been shown to decrease the inflammation associated with PD in uncontrolled studies 73, 74 and theoretically offers benefit for inflammatory lesions associated with PD ( Figure 1) . A small Italian clinical trial with short follow-up did not demonstrate convincing evidence of therapeutic benefit when added to dexamethasone and lidocaine. 44 Prior to completion of the full study, bovine superoxide dismutase was removed from the market as a result of allergic reactions noted in other studies. These authors did demonstrate decreased plaque size, curvature and pain when a 3-week treatment with verapamil and liposomal superoxide dismutase delivered to the site of the plaque by electromotive drug administration (EMDA). A second RCT with human recombinant superoxide dismutase using a crossover design suggests some benefit, including pain relief. 45 The very short (12 week) observation period and small sample size (39 patients) limited this study's power to detect significant differences. Peyronie's disease: diagnosis and treatment JF Smith et al strate improvement in curvature or plaque size in the verapamil arm relative to saline placebo. 37 The benefit of using EMDA to apply verapamil or other medications stems from its tolerability and ease of application; however, none of the treatments applied by this route have been shown to be consistently better than placebo.
Verapamil.
Di Stasi et al. 34 demonstrated in a double-blind, randomized trial that electromotive verapamil therapy with dexamethasone significantly decreased penile curvature (50 vs 0% decrease, Po0.0001) and plaque size (60 vs 0% decrease, Po0.0001) relative to a lidocaine control when given as four treatments per
Intralesional therapy
Interferon a-2b. The interest in interferon (IFN)-a2b arose from in vitro experiments that demonstrated decreased production of extracellular matrix collagen and increased collagenase in fibroblasts derived from Peyronie's plaques 75, 76 (Figure 2) . In a nonrandomized, unblinded, prospective cohort (n ¼ 117), Hellstrom et al. 77 demonstrated a significant decrease in curvature and plaque size in men treated with intralesional IFN-a. Injections of 5 Â 10 6 U IFN-a-2b in 10 ml saline vs 10 ml saline placebo were given every other week for 12 weeks (six injections) with follow-up 4 weeks after the final treatment. This observational study did not adjust for possible confounding effects of age, medical comorbidities and duration of disease, leading to potentially biased estimates of effectiveness. Although the treatment was associated with flu-like symptoms (fever, chills and arthralgias), minor penile swelling and sinusitis, all resolved within 36 h of treatment with over-the-counter nonsteroidal anti-inflammatories. A recent small RCT (n ¼ 30) did not demonstrate benefit with intralesional IFN-a-2b in combination with vitamin E over the 6-month study period. 38 Although the data are mixed, IFN-a may provide benefit for some men.
Collagenase. A single institution case series of intralesional clostridial collagenase among 25 men has demonstrated decreases in plaque size, and penile angulation when men were followed for approximately 6 months. 78 Adverse effects occurred in 80% of the men, but were generally mild, and consisted of penile pain, edema and ecchymosis. All the adverse effects were resolved with conservative management. An earlier observational of 20 patients demonstrated improvement in terms of pain and ability to have intercourse. 79 The benefit of intralesional collagenase needs to be confirmed by RCTs prior to its implementation in the routine care of men with PD.
Verapamil. Calcium channel blockers have been demonstrated to inhibit production of extracellular matrix proteins and decrease production of collagen and TGF-b. Intralesional therapy was chosen during early studies because tissue concentrations necessary to exert an effect were 100-fold higher than safe serum levels. 32, 80 In the first clinical trial evaluating intralesional verapamil vs placebo, 14 men with PD for more than 1 year were followed for 4-6 months after randomization. 32 Each man randomized to the treatment arm received 4-8 injections into the penile plaque weekly for 6 months. Verapamil injections resulted in decreased plaque size (Po0.04) and improved quality of erections (Po0.02), with a trend toward decreased curvature (Po0.07).
Cavallini et al. 33 randomized 60 men to intralesional verapamil (10 mg per week over 10 weeks) with either oral L-carnitine (1 g Po0 .01) relative to the verapamil with tamoxifen group. It has been hypothesized that the volume of verapamil injected is associated with the greatest benefit. An RCT comparing three different dilutions of verapamil demonstrated the greatest decrease in plaque size and curvature in the group receiving 20 ml of saline with verapamil relative to the groups that had 4 or 10 ml injected. 35 The question of whether volume of injected fluid or verapamil explains the treatment effect has not been adequately answered by these trials. Adding a placebo arm with 10-20 ml of saline in future trials would be helpful to clarify this issue.
Although intralesional verapamil injections are supported by consistent RCT data (five out of six show benefit), future studies should follow Consolidated Standards of Reporting Trials (CONSORT) guidelines by consistently reporting treatment allocation, losses to follow-up and the type of analysis performed. 81, 82 The CONSORT guidelines were developed to allow readers to interpret each study design, analytic techniques chosen and results to assess the validity of study findings. Studies that do not follow these guidelines have been shown to provide biased estimates of treatment effect. 82 Other nonsurgical therapy Shock wave therapy. A novel approach to the management of PD has been to utilize extracorporeal shock wave therapy to treat penile plaques. Although a retrospective cohort of 25 patients 76% reported significantly decreased penile angulation over the follow-up period (mean 8.5 months), 83 shock wave therapy was associated with minor skin hematoma (76%) and urethral bleeding (8%) that resolved with conservative management. The treatment was not associated with pain and local or regional anesthesia was not necessary. In a second study, a case series of 24 patients undergoing plaque lithotripsy, who had previously failed medical management, demonstrated a significant decrease in penile angulation in 17%. 84 The treatment was 85 A recent attempt at meta-analysis of these results suggests an overall benefit in decreasing penile pain and improving sexual function. 86 These data do not provide convincing evidence of benefit with this therapy.
Penile traction. Two abstracts presented at the 2008 American Urological Association National Meeting have reported promising results for penile traction therapy as an adjunct to oral and intralesional therapy for PD. 87, 88 In one, an uncontrolled, prospective study using combined intralesional verapamil with penile traction, applied, on average for 3.6 h per day, was associated with subjective decreases in penile curvature; however these results did not achieve statistical significance. 87 A second prospective, uncontrolled study using penile traction for men with mild-moderate curvature (o501) demonstrated decreased curvature and increased penile length (1.4 cm) over the course of the 1-year treatment interval. 88 As these methods are refined, they may offer patients an effective way to minimize the loss of penile length and decrease the penile curvature that causes much of the functional and psychological distress in Peyronie's disease.
Radiation therapy. Although irradiation of the plaque has been performed, this therapy has no proven role in the management of PD and likely causes significant harm. The most recent study examining the effects of radiation therapy on PD was an uncontrolled case series of 265 men. The authors demonstrated a decrease in plaque size in 9-30%. This is consistent with descriptions of the natural history of PD and cannot be taken as proof that the therapy is effective. An older study of 177 men using radiotherapy did not demonstrate significant benefit. 89 
Summary of medical options
L-carnitine and Potaba treatment are the bestsupported oral medications, but evidence is far from convincing. Effective treatment with intralesional verapamil has been supported by the largest number of RCTs, but EMDA application of verapamil or intralesional IFN-a may also be effective. New effective therapies are needed that are easy to administer, low cost and have few side effects.
Surgical therapy
Indications for surgical treatment. The primary indications for surgical treatment of Peyronie's disease relate to penile curvature severity or penile instability due to hourglass or other narrowing deformities. Although some curvature is severe enough to prohibit intromission, lesser curvatures may still result in pain during intercourse for either partner. Narrowing of the penile shaft can also lead to difficulties with intromission due to inadequate tumescence distal to the lesion, or because of buckling of the penis from inadequate longitudinal rigidity. Although the majority of men cite the physical limitation placed upon them due to penile curvature, some men are merely unhappy with the appearance of their penis after developing Peyronie's disease-another valid reason for intervention.
Preoperative evaluation and counseling. Prior to proceeding with surgical treatment, three key elements must be assessed: (1) erectile capacity, (2) the severity and directionality of curvature and Knowledge of these elements is crucial to selecting the appropriate intervention for a particular patient. Other means of assessing penile curvature include self-description and the provision of photographs of the erect penis, although both methods may underestimate curvature. If the former is relied upon, we recommend providing patients with a series of schematic drawings of the penis with varying degrees of curvature from which they can select. If the latter method is relied upon, patients are encouraged to provide multiple views of the penis. Most patients' expectations from surgery include the return of a functional erection; specifically, a penis that is straight and rigid enough for normal sexual activity. There are, however, a few caveats regarding patient expectation regarding penile length, namely, that as a result of the disease process itself and certain procedures that correct curvature, the penis may become foreshortened. To provide realistic penile length expectations, practitioners should emphasize the stretched penile length, and involve patients in this part of the physical examination, especially if the planned procedure is a plication. Although plication procedures have the lowest risk of causing or exacerbating ED, they may be inappropriate for some patient's who are most distressed by their loss of penile length.
Surgical options. To date, there have been no head-to-head comparisons of different techniques for penile straightening in men with Peyronie's. Evidence suggesting one technique is superior to another is lacking, however, based on large cases series it seems that some techniques may be better suited to certain patients.
The placement of a penile prosthesis with or without grafting and/or molding is a viable surgical option for men with Peyronie's disease who have diminished erectile capacity. 90 However, for those men with adequate erectile function, mechanical straightening or reconstruction of the penis is the most appropriate surgical option and will be the focus of this review. In general, the straightening of a curved or narrowed penis may be divided into two categories: procedures that shorten the convex side of the penis, and those that lengthen the concave side.
Tunical shortening procedures. Originally described by Nesbit in 1965, this procedure requires the excision of an ellipse of tunica albuginea at the most prominent point of curvature. 91 Closure of the defect in the tunica causes shortening of the convex side of the penis with resultant straightening. A modification of this technique, the Yachia procedure utilizes the same principle of convex shortening, but avoids tissue excision by making a longitudinal incision in the tunica that is subsequently closed horizontally in the fashion of Heineke-Mikulicz. 92 Although patient satisfaction rates for these procedures have been reported to be as high as 100%, many series demonstrate rates lower than 80%. Perhaps some of the dissatisfaction with these procedures stems from the need to elevate the neurovascular bundle (to greater or lesser degrees), and to disrupt the integrity of the corpus cavernosa, which can lead to sensory loss and ED, respectively. Indeed, in some series, loss of sensation and postoperative ED have been reported in as many as 24 and 12%, respectively.
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Figure 4 Excision of plaque. Reproduced with Permission. 98 Create an artificial erection by an injection with normal saline into the corpus cavernosum through a 21 G scalp vein needle. Mark the site of greatest curvature and area(s) of narrowing; an 'H' is then drawn (panel a). The middle bar marks the centre of the curvature and the side bars extend along the axis of the penis; these markings can also be used to address areas of narrowing, so that their length and direction will depend on the characteristics of curvature. The penile site (panel b) is then opened along the markings and spread open so that the size of the defect both longitudinally and transversely can be measured.
Peyronie's disease: diagnosis and treatment JF Smith et al Penile plication utilizes well-placed sutures to gather tissue on the convex side of the tunica. Although a variant of this procedure was initially described by Nesbit, it was popularized in later years as a means of avoiding both tunical disruption and dissection of the neurovascular bundle. 95 In the 16-dot technique described by Gholami (Figure 3 ), 2-3 pairs of sutures are placed in a vertical mattress fashion, in parallel with the urethra. 96 Aided by intracorporal injection of papaverine to induce Figure 5 Construction of graft coverage. Reproduced with permission. 98 To determine vein length, for example, if the H incision measures 5 cm wide by 3 cm high, choose a vein length ¼ 17 cm, to yield 5 Â 3 cm segments with a small surplus of material. The vein has the least contraction of any of the biological graft materials; it is easier to tailor other graft choices to size and this will be discussed below. Vein preparation (a-d): using a Silastic block, the vein's adventitia is removed and the vein is divided into segments. Tributary sites are opened during the division to minimize postoperative leakage. Using short 25 G needles is helpful in fixing the vein to the block while working. 5-0 polyglyconate is used to anchor segments together and the sides are joined using VCS titanium staples. The graft is kept moist until it is used. Many other graft materials are available; as these contract after placement, we recommend tailoring a graft that gives a final size of E25% larger than the defect. Such procedures involve the incision of the plaque with insertion of graft material to repair the defect. Naturally, this incision and grafting is performed at the site of maximum concavity resulting in lengthening of the penis. Prerequisite to this approach is erectile capacity that can tolerate disrupting the integrity of the tunica albuginea. The standard approach includes mobilizing an appropriate segment of the neurovascular bundle, typically 1 cm proximal and distal to the plaque. Historically, plaques were often excised, however, given the increased risk of ED, an 'H'-shaped incision alone should be used, except for the most severely calcified lesions (Figure 4 ). Further, care should be taken to minimize injury to the underlying smooth muscle and tunical contents. 99 Three types of graft material have been classically described: (1) synthetic grafts (Dacron, Gore-tex), (2) allografts or xenografts (cadeveric pericardium or porcine small intestinal submucosa (SIS)) and (3) autologous tissue grafts (saphenous vein, dermis, tunica vaginalis). The first of these has fallen out of favor due to their higher infection rates and the propensity of synthetic materials to cause fibrosis and contracture. 100 The use of donor materials in the form of allo-or xenografts has gained considerable popularity given their convenience. The use of 'off the shelf' materials avoids the need to harvest autologous graft material, avoiding the attendant morbidity of a secondary surgical site. In particular, the use of SIS has resulted in patient satisfaction rates as high as 98%, with only 21% of patients experiencing postoperative ED. 101 However, other reports have noted high complication rates with SIS, including hematoma, pain, infection and a particularly high rate of penile shortening (63%). 102 The use of cadaveric fascia lata (Tutoplast) 103 and foreskin flaps 104 has shown promise as graft materials, however, long-term follow-up and confirmatory studies are required. The use of autologous graft Figure 6 Graft insertion into defect. Reproduced with permission. 98 The corners are sutured into place first, using 4-0 polyglyconate. The remainder of the graft is sutured into place in a running, locking fashion (panels a and b). Tip: Leaks tend to occur at the corners where the running suture goes around the previously placed corner knots. This can be avoided by not locking the suture at these sites and by advancing the suture very little in these areas. An artificial erection should confirm an appropriate shape and will identify any leaks in the graft; 5-0 polyglyconate is used to close the leaks. Once the graft is watertight, a few sutures are placed to return the neurovascular bundles to their original site. An artificial erection is created again by injection with normal saline. If the penis is not straight, plication sutures (2-0 polyethylene terephthalate, Ticron, Tyco Healthcare, Mansfield, MA) are placed to straighten the penis and protect the graft from bulging. Several interrupted subcutaneous sutures are placed using 5-0 polyglyconate, then the skin is closed using two running, locking 5-0 polyglycolic acid sutures.
Peyronie's disease: diagnosis and treatment JF Smith et al materials may provide advantage due to their ease of incorporation into the host tissue, with decrease local reaction and fibrosis. Autologous tunica albuginea transplants in three small case series have been used with some success. [105] [106] [107] Of the autologous materials, saphenous vein is commonly used due to its relative ease and reliability of harvest and large surface area ( Figure 5 ). Although high rates of patient satisfaction have been achieved with this material, its harvest causes additional operative morbidity and risk. 108 The best graft material has yet to be determined, as none of the currently available materials has been compared in head-to-head trials. Clearly, each material has its attendant advantages and disadvantages. Ultimately, the choice of graft material should be based upon surgeon and patient preferences after a detailed discussion of risks, benefits and alternatives. 100 Penile prosthetics. Penile prostheses are the standard of care in patients with ED and penile curvature or severe penile defects that require grafting to repair with or without preexisting ED. 109 After placing the prosthesis, if residual curvature isX451, 90 additional maneuvers are necessary to straighten the penis. Incision of plaque followed by graft is one effective approach. 110 The technique of 'modeling' the fully inflated prosthesis is successful (90%) in straightening the penis, but is associated with a risk of urethral injury (4%). 111 Satisfaction rates in the overall population of men who receive penile prostheses are in the range of 90%; 112 however, men with PD may have somewhat lower satisfaction rates (73-75%). 112 The average lifespan of a prosthesis is approximately 10 years, with a 4% mechanical failure at 5 years and 40% failure by 15 years. 113 Success as defined by complete penile straightening ranges from 80 to 93% [114] [115] [116] [117] ( Figure 6 ).
Summary of surgical therapeutic options. In summary, the surgical treatment of Peyronie's disease is a viable and recommended alternative for men with compromised sexual function due to severe curvature or a lesion causing penile instability. The choice of corrective procedure should be tailored to each patient after completing a detailed evaluation of disease severity and sexual function.
Conclusion
PD is a disorder of the tunica albuginea resulting in penile deformity and variable degrees of psychosocial distress and sexual disability. 
